Healthcare of Ontario Pension Plan Trust Fund Purchases New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 105,000 shares of the biopharmaceutical company’s stock, valued at approximately $3,881,000. Healthcare of Ontario Pension Plan Trust Fund owned about 0.08% of Halozyme Therapeutics as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Principal Securities Inc. bought a new position in Halozyme Therapeutics in the fourth quarter valued at about $34,000. First Horizon Advisors Inc. boosted its holdings in Halozyme Therapeutics by 24.5% in the fourth quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 293 shares during the last quarter. Parkside Financial Bank & Trust bought a new position in Halozyme Therapeutics in the fourth quarter valued at about $64,000. Headlands Technologies LLC boosted its holdings in Halozyme Therapeutics by 1,068.2% in the fourth quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 1,613 shares during the last quarter. Finally, Quadrant Capital Group LLC boosted its holdings in Halozyme Therapeutics by 22.4% in the fourth quarter. Quadrant Capital Group LLC now owns 3,414 shares of the biopharmaceutical company’s stock valued at $126,000 after acquiring an additional 624 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Up 1.2 %

NASDAQ:HALO opened at $50.27 on Wednesday. Halozyme Therapeutics, Inc. has a fifty-two week low of $32.83 and a fifty-two week high of $53.00. The company has a debt-to-equity ratio of 8.44, a current ratio of 6.64 and a quick ratio of 5.36. The stock has a market capitalization of $6.40 billion, a PE ratio of 20.77, a price-to-earnings-growth ratio of 0.50 and a beta of 1.28. The business’s 50-day simple moving average is $43.22 and its 200-day simple moving average is $39.82.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.07. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The business had revenue of $195.88 million for the quarter, compared to analyst estimates of $201.72 million. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post 3.66 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on HALO shares. StockNews.com upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. Piper Sandler cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their target price for the stock from $48.00 to $51.00 in a report on Friday, June 7th. TD Cowen started coverage on Halozyme Therapeutics in a report on Thursday, February 29th. They set an “outperform” rating and a $54.00 target price on the stock. JMP Securities reduced their target price on Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 8th. Finally, Benchmark restated a “buy” rating and set a $50.00 target price on shares of Halozyme Therapeutics in a report on Tuesday, April 16th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.13.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Matthew L. Posard sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now owns 109,755 shares of the company’s stock, valued at approximately $5,488,847.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 30,000 shares of company stock valued at $1,338,800 in the last 90 days. 2.70% of the stock is currently owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.